Edition:
United Kingdom

AveXis Inc (AVXS.OQ)

AVXS.OQ on NASDAQ Stock Exchange Global Select Market

209.92USD
23 Apr 2018
Change (% chg)

$3.44 (+1.67%)
Prev Close
$206.48
Open
$207.20
Day's High
$210.10
Day's Low
$205.98
Volume
248,007
Avg. Vol
259,960
52-wk High
$213.68
52-wk Low
$65.55

Latest Key Developments (Source: Significant Developments)

Adage Capital Partners GP LLC Reports 6.04 Percent Stake In Avexis
Friday, 20 Apr 2018 

April 20 (Reuters) - AveXis Inc ::ADAGE CAPITAL PARTNERS GP LLC REPORTS 6.04 PERCENT STAKE IN AVEXIS INC AS OF APRIL 11 - SEC FILING.ADAGE CAPITAL PARTNERS GP LLC SAYS ACQUIRED AVEXIS INC SHARES OF COMMON STOCK FOR INVESTMENT PURPOSES.  Full Article

AveXis Says Merger Deal With Novartis Includes That Under Certain Circumstances, Co Will Pay $284 Mln Termination Fee
Monday, 9 Apr 2018 

April 9 (Reuters) - AveXis Inc::AVEXIS - MERGER DEAL WITH NOVARTIS INCLUDES THAT UNDER CERTAIN SPECIFIED CIRCUMSTANCES, CO WILL BE REQUIRED TO PAY $284 MLN TERMINATION FEE TO NOVARTIS.AVEXIS INC - IN CASE OF TERMINATION OF DEAL, NOVARTIS WILL BE REQUIRED TO PAY TO CO A "REVERSE TERMINATION FEE" EQUAL TO $437 MLN - SEC FILING.  Full Article

Novartis Enters Agreement To Acquire AveXis For $8.7 Bln
Monday, 9 Apr 2018 

April 9 (Reuters) - Novartis AG ::NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN TO TRANSFORM CARE IN SMA AND EXPAND POSITION AS A GENE THERAPY AND NEUROSCIENCE LEADER.NOVARTIS ENTERS AGREEMENT TO ACQUIRE AVEXIS INC. FOR USD 8.7 BN TO TRANSFORM CARE IN SMA AND EXPAND POSITION AS A GENE THERAPY AND NEUROSCIENCE LEADER.NOVARTIS AG <<>>- ‍ASSUMING MID 2018 COMPLETION, ACQUISITION IMPACT WOULD BE SLIGHTLY NEGATIVE TO CORE OPERATING INCOME IN 2018 AND 2019.  Full Article

AveXis Enters Agreement To Be Acquired By Novartis For $8.7 Bln
Monday, 9 Apr 2018 

April 9 (Reuters) - AveXis Inc ::AVEXIS ENTERS AGREEMENT TO BE ACQUIRED BY NOVARTIS AG FOR $8.7 BILLION.SAYS OFFER REPRESENTS A PREMIUM OF 88 PERCENT TO AVEXIS' CLOSING PRICE ON APRIL 6, 2018.ENTERED AGREEMENT AND PLAN OF MERGER WITH NOVARTIS PURSUANT TO WHICH NOVARTIS WILL ACQUIRE AVEXIS FOR $218 PER SHARE.SAYS TRANSACTION WAS UNANIMOUSLY APPROVED BY BOARDS OF DIRECTORS OF BOTH COMPANIES..  Full Article

Avexis Gene Therapy Awarded Sakigake Designation For Spinal Muscular Atrophy Type 1
Tuesday, 27 Mar 2018 

March 27 (Reuters) - Avexis Inc ::AVEXIS GENE THERAPY AWARDED SAKIGAKE DESIGNATION FOR SPINAL MUSCULAR ATROPHY TYPE 1.AVEXIS INC - DESIGNATION WAS BASED ON DATA FROM PHASE 1 CLINICAL TRIAL OF CO'S PROPRIETARY GENE THERAPY​.AVEXIS INC - ‍JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE AWARDED INITIAL PRODUCT CANDIDATE, AVXS-101, SAKIGAKE FOR TREATMENT OF SMA TYPE 1​.  Full Article

Avexis Provides Details On License Agreement with Généthon
Tuesday, 13 Mar 2018 

March 13 (Reuters) - Avexis Inc ::AVEXIS - UNDER LICENSE AGREEMENT, CO HAS PAID OR IS REQUIRED TO PAY, INITIAL FEE OF $4.0 MILLION, UP TO $11.0 MILLION IN MILESTONE FEES FOR LICENSED PRODUCTS.  Full Article

Avexis Q4 Loss Per Share $2.55
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Avexis Inc ::AVEXIS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL AND OPERATING RESULTS.Q4 LOSS PER SHARE $2.55.‍ON TRACK TO REQUEST PRE-BLA MEETING WITH FDA IN Q2 2018​.‍INTENDS TO INITIATE PIVOTAL TRIAL IN SMA TYPE 1 IN EUROPE AND MULTI-NATIONAL PRE-SYMPTOMATIC SMA STUDY IN FIRST HALF OF 2018​.‍ANTICIPATES IND SUBMISSIONS FOR RETT SYNDROME AND GENETIC ALS IN LATE 2018/EARLY 2019​.  Full Article

Avexis Announces Proposed Public Offering Of Common Stock
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.AVEXIS INC - INTENDS TO OFFER AND SELL UP TO $400 MILLION OF SHARES OF COMMON STOCK IN UNDERWRITTEN PUBLIC OFFERING.  Full Article

Avexis Announces Expanded Clinical Development Program For AVXS-101 In Spinal Muscular Atrophy
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Avexis Inc ::AVEXIS ANNOUNCES EXPANDED CLINICAL DEVELOPMENT PROGRAM FOR AVXS-101 IN SPINAL MUSCULAR ATROPHY.AVEXIS - TO EXPAND STUDY OF AVXS-101 INTO ADDITIONAL SMA POPULATIONS INCLUDING PRE-SYMPTOMATIC, OLDER PEDIATRIC TYPE 2 AND TYPE 3 SMA PATIENTS.AVEXIS INC - ‍PLANS TO INITIATE THREE STUDIES TO FURTHER EVALUATE AVXS-101, INCLUDING IN NEW SMA PATIENT POPULATIONS​.AVEXIS INC - ‍EXPECTS TO INITIATE PIVOTAL TRIAL OF AVXS-101 IN SMA TYPE 1 IN EUROPE​ IN FIRST HALF OF 2018.  Full Article

Regenxbio And Avexis Announce Expansion Of Relationship For Spinal Muscular Atrophy treatments
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Avexis Inc ::REGENXBIO AND AVEXIS ANNOUNCE EXPANSION OF RELATIONSHIP THROUGH AMENDED LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF TREATMENTS FOR SPINAL MUSCULAR ATROPHY.REGENXBIO INC - COULD RECEIVE UP TO $260 MILLION, INCLUDING $140 MILLION IN GUARANTEED UPFRONT AND ANNUAL PAYMENTS.REGENXBIO INC - AMENDED AGREEMENT PERMITS ASSIGNMENT BY AVEXIS UPON A CHANGE OF CONTROL WITHOUT REGENXBIO'S CONSENT.REGENXBIO INC - AVEXIS ACQUIRES EXCLUSIVE RIGHTS TO ENTIRE NAV TECHNOLOGY PLATFORM FOR DEVELOPMENT OF TREATMENTS FOR SMA.REGENXBIO - FOR PRODUCT DEVELOPED FOR TREATMENT OF SMA USING NAV AAV9 VECTOR, CO WILL RECEIVE MID-SINGLE TO LOW DOUBLE-DIGIT ROYALTIES ON NET SALES.  Full Article

BRIEF-Adage Capital Partners GP LLC Reports 6.04 Percent Stake In Avexis

* ADAGE CAPITAL PARTNERS GP LLC REPORTS 6.04 PERCENT STAKE IN AVEXIS INC AS OF APRIL 11 - SEC FILING